跳至主要内容
临床试验/NCT03103620
NCT03103620已完成不适用

Safety And Effectiveness Evaluation Of COBRA PzF™ Coronary Stent System: A French Observational Postmarketing Registry

CeloNova BioSciences, Inc.15 个研究点 分布在 1 个国家目标入组 1,027 人开始时间: 2015年9月10日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
1,027
试验地点
15
主要终点
MACE

研究概览

简要总结

A multi-center, prospective, consecutive enrolled, observational registry. The population being studied includes all patients undergoing treatment of "de novo" lesions in native coronary vessels, saphenous vein graft and/or arterial bypass conduits with the COBRA PzF coronary stent system. The registry will primarily assess the rate of MACE (cardiac death, myocardial infarction and clinically driven target lesion revascularization.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient has given oral consent to participate in the registry Patient is implanted with a COBRA PzF stent Target lesion(s) is/are "de novo"

排除标准

  • Pregnancy Age <18 years Refusal or inability to give oral consent

结局指标

主要结局

MACE

时间窗: 12 months

Composite clinical endpoint of cardiac death, myocardial infarction, and clinically driven target lesion revascularization

次要结局

  • Stent thrombosis(12 months)
  • TVR and TLR(12 months)
  • DAPT(12 months)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (15)

Loading locations...

相似试验